Ontology type: schema:ScholarlyArticle
2022-05-06
AUTHORST. Hagenacker, U. Schara-Schmidt, C. Kleinschnitz
ABSTRACTBackgroundThe 5q-associated spinal muscular atrophy (SMA) affects ~ 80–120 newborns annually. The disease is characterized by progressive paresis involving the bulbar and respiratory musculatures. The phenotypes are very heterogeneous ranging from severe courses with early death in the first years of life to loss of gait in older age.ObjectiveThere are now an increasing number of causally targeted therapies available that can either directly interfere with the transcription of the gene causing the disease or replace the homozygous loss of the SMN1 gene. This work aims to elucidate the current state of therapy in different groups of patients with SMA.Material and methodsPresentation of clinical trials and basic studies with a focus on patients with disease onset in adulthood.ResultsThe clinical studies all show improvement or stabilization of motor function; however, in individual cases, the burden of the therapy for severely immobilized patients must be considered in addition to the efficacy in the treatment decision. Even if the drugs show a good safety profile, observations on the long-term efficacy and safety of the new substance classes are still lacking.ConclusionThe study landscape shows a good efficacy of the currently approved therapies across all degrees of severity and age groups. Due to the lack of comparative studies, the decision on the appropriate therapy should therefore be made according to an individual risk-benefit assessment. More... »
PAGES549-556
http://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1
DOIhttp://dx.doi.org/10.1007/s00115-022-01295-1
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1147664516
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/35522309
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gait",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infant, Newborn",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Muscular Atrophy, Spinal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Oligonucleotides",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Phenotype",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk Assessment",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland"
],
"type": "Organization"
},
"familyName": "Hagenacker",
"givenName": "T.",
"id": "sg:person.01320640500.40",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320640500.40"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Kinderheilkunde 1, Abteilung f\u00fcr Neurop\u00e4diatrie, Essen, Deutschland",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Kinderheilkunde 1, Abteilung f\u00fcr Neurop\u00e4diatrie, Essen, Deutschland"
],
"type": "Organization"
},
"familyName": "Schara-Schmidt",
"givenName": "U.",
"id": "sg:person.01133657416.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133657416.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Universit\u00e4tsmedizin Essen, Klinik f\u00fcr Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr.\u00a055, 45147, Essen, Deutschland"
],
"type": "Organization"
},
"familyName": "Kleinschnitz",
"givenName": "C.",
"id": "sg:person.01004271214.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004271214.05"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00115-020-00919-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1127514887",
"https://doi.org/10.1007/s00115-020-00919-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ng0797-265",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051068967",
"https://doi.org/10.1038/ng0797-265"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00234-019-02189-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1112731519",
"https://doi.org/10.1007/s00234-019-02189-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s13023-021-01903-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1138847071",
"https://doi.org/10.1186/s13023-021-01903-4"
],
"type": "CreativeWork"
}
],
"datePublished": "2022-05-06",
"datePublishedReg": "2022-05-06",
"description": "BackgroundThe 5q-associated spinal muscular atrophy (SMA) affects ~\u00a080\u2013120 newborns annually. The disease is characterized by progressive paresis involving the bulbar and respiratory musculatures. The phenotypes are very heterogeneous ranging from severe courses with early death in the first years of life to loss of gait in older age.ObjectiveThere are now an increasing number of causally targeted therapies available that can either directly interfere with the transcription of the gene causing the disease or replace the homozygous loss of the SMN1 gene. This work aims to elucidate the current state of therapy in different groups of patients with SMA.Material and methodsPresentation of clinical trials and basic studies with a\u00a0focus on patients with disease onset in adulthood.ResultsThe clinical studies all show improvement or stabilization of motor function; however, in individual cases, the burden of the therapy for severely immobilized patients must be considered in addition to the efficacy in the treatment decision. Even if the drugs show a\u00a0good safety profile, observations on the long-term efficacy and safety of the new substance classes are still lacking.ConclusionThe study landscape shows a good efficacy of the currently approved therapies across all degrees of severity and age groups. Due to the lack of comparative studies, the decision on the appropriate therapy should therefore be made according to an individual risk-benefit assessment.",
"genre": "article",
"id": "sg:pub.10.1007/s00115-022-01295-1",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1018193",
"issn": [
"0028-2804",
"1433-0407"
],
"name": "Der Nervenarzt",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "93"
}
],
"keywords": [
"spinal muscular atrophy",
"individual risk-benefit assessment",
"loss of gait",
"good safety profile",
"long-term efficacy",
"risk-benefit assessment",
"degree of severity",
"progressive paresis",
"severe course",
"appropriate therapy",
"safety profile",
"respiratory musculature",
"disease onset",
"clinical trials",
"motor function",
"clinical studies",
"treatment decisions",
"early death",
"new substance class",
"better efficacy",
"muscular atrophy",
"therapy",
"age groups",
"older age",
"patients",
"SMN1 gene",
"homozygous loss",
"efficacy",
"disease",
"first year",
"individual cases",
"paresis",
"atrophy",
"newborns",
"group",
"ObjectiveThere",
"different groups",
"trials",
"substance classes",
"severity",
"study",
"drugs",
"death",
"age",
"musculature",
"adulthood",
"gait",
"burden",
"onset",
"genes",
"MethodsPresentation",
"basic studies",
"phenotype",
"safety",
"loss",
"comparative study",
"years",
"course",
"assessment",
"cases",
"life",
"lack",
"improvement",
"transcription",
"profile",
"function",
"current state",
"addition",
"decisions",
"number",
"degree",
"focus",
"stabilization",
"observations",
"materials",
"state",
"class",
"work",
"landscape",
"study landscape"
],
"name": "Genetisch basierte Therapien bei spinaler Muskelatrophie",
"pagination": "549-556",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1147664516"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00115-022-01295-1"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"35522309"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00115-022-01295-1",
"https://app.dimensions.ai/details/publication/pub.1147664516"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:11",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_934.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00115-022-01295-1"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00115-022-01295-1'
This table displays all metadata directly associated to this object as RDF triples.
205 TRIPLES
21 PREDICATES
117 URIs
105 LITERALS
15 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s00115-022-01295-1 | schema:about | N0018858626494a3285ff78264118adda |
2 | ″ | ″ | N69e9f7ea115f4907a66916df7973f76f |
3 | ″ | ″ | N6e158624588c46b28fb861c21e24f2d0 |
4 | ″ | ″ | Nb0155d769e99461fb4d39f302649b0f8 |
5 | ″ | ″ | Nb40607d1debb4bdea3bccf2814b92633 |
6 | ″ | ″ | Ndfa25e71d03d46b49c6ffc300f57625f |
7 | ″ | ″ | Ne7a14ec807974654a75498df76e52a74 |
8 | ″ | ″ | Neeacd45441184447b1ac259b2523b476 |
9 | ″ | ″ | anzsrc-for:11 |
10 | ″ | ″ | anzsrc-for:1103 |
11 | ″ | schema:author | N8a3fc07924324bb18ed31267c5c2b3db |
12 | ″ | schema:citation | sg:pub.10.1007/s00115-020-00919-8 |
13 | ″ | ″ | sg:pub.10.1007/s00234-019-02189-x |
14 | ″ | ″ | sg:pub.10.1038/ng0797-265 |
15 | ″ | ″ | sg:pub.10.1186/s13023-021-01903-4 |
16 | ″ | schema:datePublished | 2022-05-06 |
17 | ″ | schema:datePublishedReg | 2022-05-06 |
18 | ″ | schema:description | BackgroundThe 5q-associated spinal muscular atrophy (SMA) affects ~ 80–120 newborns annually. The disease is characterized by progressive paresis involving the bulbar and respiratory musculatures. The phenotypes are very heterogeneous ranging from severe courses with early death in the first years of life to loss of gait in older age.ObjectiveThere are now an increasing number of causally targeted therapies available that can either directly interfere with the transcription of the gene causing the disease or replace the homozygous loss of the SMN1 gene. This work aims to elucidate the current state of therapy in different groups of patients with SMA.Material and methodsPresentation of clinical trials and basic studies with a focus on patients with disease onset in adulthood.ResultsThe clinical studies all show improvement or stabilization of motor function; however, in individual cases, the burden of the therapy for severely immobilized patients must be considered in addition to the efficacy in the treatment decision. Even if the drugs show a good safety profile, observations on the long-term efficacy and safety of the new substance classes are still lacking.ConclusionThe study landscape shows a good efficacy of the currently approved therapies across all degrees of severity and age groups. Due to the lack of comparative studies, the decision on the appropriate therapy should therefore be made according to an individual risk-benefit assessment. |
19 | ″ | schema:genre | article |
20 | ″ | schema:isAccessibleForFree | false |
21 | ″ | schema:isPartOf | N87d448382a4945448b8b5a91cfdcc072 |
22 | ″ | ″ | Nfbe7e26dab9e4e1884114d721f868879 |
23 | ″ | ″ | sg:journal.1018193 |
24 | ″ | schema:keywords | MethodsPresentation |
25 | ″ | ″ | ObjectiveThere |
26 | ″ | ″ | SMN1 gene |
27 | ″ | ″ | addition |
28 | ″ | ″ | adulthood |
29 | ″ | ″ | age |
30 | ″ | ″ | age groups |
31 | ″ | ″ | appropriate therapy |
32 | ″ | ″ | assessment |
33 | ″ | ″ | atrophy |
34 | ″ | ″ | basic studies |
35 | ″ | ″ | better efficacy |
36 | ″ | ″ | burden |
37 | ″ | ″ | cases |
38 | ″ | ″ | class |
39 | ″ | ″ | clinical studies |
40 | ″ | ″ | clinical trials |
41 | ″ | ″ | comparative study |
42 | ″ | ″ | course |
43 | ″ | ″ | current state |
44 | ″ | ″ | death |
45 | ″ | ″ | decisions |
46 | ″ | ″ | degree |
47 | ″ | ″ | degree of severity |
48 | ″ | ″ | different groups |
49 | ″ | ″ | disease |
50 | ″ | ″ | disease onset |
51 | ″ | ″ | drugs |
52 | ″ | ″ | early death |
53 | ″ | ″ | efficacy |
54 | ″ | ″ | first year |
55 | ″ | ″ | focus |
56 | ″ | ″ | function |
57 | ″ | ″ | gait |
58 | ″ | ″ | genes |
59 | ″ | ″ | good safety profile |
60 | ″ | ″ | group |
61 | ″ | ″ | homozygous loss |
62 | ″ | ″ | improvement |
63 | ″ | ″ | individual cases |
64 | ″ | ″ | individual risk-benefit assessment |
65 | ″ | ″ | lack |
66 | ″ | ″ | landscape |
67 | ″ | ″ | life |
68 | ″ | ″ | long-term efficacy |
69 | ″ | ″ | loss |
70 | ″ | ″ | loss of gait |
71 | ″ | ″ | materials |
72 | ″ | ″ | motor function |
73 | ″ | ″ | muscular atrophy |
74 | ″ | ″ | musculature |
75 | ″ | ″ | new substance class |
76 | ″ | ″ | newborns |
77 | ″ | ″ | number |
78 | ″ | ″ | observations |
79 | ″ | ″ | older age |
80 | ″ | ″ | onset |
81 | ″ | ″ | paresis |
82 | ″ | ″ | patients |
83 | ″ | ″ | phenotype |
84 | ″ | ″ | profile |
85 | ″ | ″ | progressive paresis |
86 | ″ | ″ | respiratory musculature |
87 | ″ | ″ | risk-benefit assessment |
88 | ″ | ″ | safety |
89 | ″ | ″ | safety profile |
90 | ″ | ″ | severe course |
91 | ″ | ″ | severity |
92 | ″ | ″ | spinal muscular atrophy |
93 | ″ | ″ | stabilization |
94 | ″ | ″ | state |
95 | ″ | ″ | study |
96 | ″ | ″ | study landscape |
97 | ″ | ″ | substance classes |
98 | ″ | ″ | therapy |
99 | ″ | ″ | transcription |
100 | ″ | ″ | treatment decisions |
101 | ″ | ″ | trials |
102 | ″ | ″ | work |
103 | ″ | ″ | years |
104 | ″ | schema:name | Genetisch basierte Therapien bei spinaler Muskelatrophie |
105 | ″ | schema:pagination | 549-556 |
106 | ″ | schema:productId | N042f70f959d640129336fba9058272fe |
107 | ″ | ″ | N52ecb9ca7981409e97b8705277b6af26 |
108 | ″ | ″ | N7f82b2ac9f044c969a66af70abde4157 |
109 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1147664516 |
110 | ″ | ″ | https://doi.org/10.1007/s00115-022-01295-1 |
111 | ″ | schema:sdDatePublished | 2022-08-04T17:11 |
112 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
113 | ″ | schema:sdPublisher | Nb97565bbe86146caaa626e9fc75665ef |
114 | ″ | schema:url | https://doi.org/10.1007/s00115-022-01295-1 |
115 | ″ | sgo:license | sg:explorer/license/ |
116 | ″ | sgo:sdDataset | articles |
117 | ″ | rdf:type | schema:ScholarlyArticle |
118 | N0018858626494a3285ff78264118adda | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
119 | ″ | schema:name | Muscular Atrophy, Spinal |
120 | ″ | rdf:type | schema:DefinedTerm |
121 | N042f70f959d640129336fba9058272fe | schema:name | dimensions_id |
122 | ″ | schema:value | pub.1147664516 |
123 | ″ | rdf:type | schema:PropertyValue |
124 | N419e38d5d5414e4c86062fe20b1d366f | rdf:first | sg:person.01133657416.38 |
125 | ″ | rdf:rest | Nc8334bcad37f48f2be0e54167351b106 |
126 | N52ecb9ca7981409e97b8705277b6af26 | schema:name | doi |
127 | ″ | schema:value | 10.1007/s00115-022-01295-1 |
128 | ″ | rdf:type | schema:PropertyValue |
129 | N69e9f7ea115f4907a66916df7973f76f | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
130 | ″ | schema:name | Humans |
131 | ″ | rdf:type | schema:DefinedTerm |
132 | N6e158624588c46b28fb861c21e24f2d0 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
133 | ″ | schema:name | Risk Assessment |
134 | ″ | rdf:type | schema:DefinedTerm |
135 | N7f82b2ac9f044c969a66af70abde4157 | schema:name | pubmed_id |
136 | ″ | schema:value | 35522309 |
137 | ″ | rdf:type | schema:PropertyValue |
138 | N87d448382a4945448b8b5a91cfdcc072 | schema:volumeNumber | 93 |
139 | ″ | rdf:type | schema:PublicationVolume |
140 | N8a3fc07924324bb18ed31267c5c2b3db | rdf:first | sg:person.01320640500.40 |
141 | ″ | rdf:rest | N419e38d5d5414e4c86062fe20b1d366f |
142 | Nb0155d769e99461fb4d39f302649b0f8 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
143 | ″ | schema:name | Adult |
144 | ″ | rdf:type | schema:DefinedTerm |
145 | Nb40607d1debb4bdea3bccf2814b92633 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
146 | ″ | schema:name | Infant, Newborn |
147 | ″ | rdf:type | schema:DefinedTerm |
148 | Nb97565bbe86146caaa626e9fc75665ef | schema:name | Springer Nature - SN SciGraph project |
149 | ″ | rdf:type | schema:Organization |
150 | Nc8334bcad37f48f2be0e54167351b106 | rdf:first | sg:person.01004271214.05 |
151 | ″ | rdf:rest | rdf:nil |
152 | Ndfa25e71d03d46b49c6ffc300f57625f | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
153 | ″ | schema:name | Gait |
154 | ″ | rdf:type | schema:DefinedTerm |
155 | Ne7a14ec807974654a75498df76e52a74 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
156 | ″ | schema:name | Phenotype |
157 | ″ | rdf:type | schema:DefinedTerm |
158 | Neeacd45441184447b1ac259b2523b476 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
159 | ″ | schema:name | Oligonucleotides |
160 | ″ | rdf:type | schema:DefinedTerm |
161 | Nfbe7e26dab9e4e1884114d721f868879 | schema:issueNumber | 6 |
162 | ″ | rdf:type | schema:PublicationIssue |
163 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
164 | ″ | schema:name | Medical and Health Sciences |
165 | ″ | rdf:type | schema:DefinedTerm |
166 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
167 | ″ | schema:name | Clinical Sciences |
168 | ″ | rdf:type | schema:DefinedTerm |
169 | sg:journal.1018193 | schema:issn | 0028-2804 |
170 | ″ | ″ | 1433-0407 |
171 | ″ | schema:name | Der Nervenarzt |
172 | ″ | schema:publisher | Springer Nature |
173 | ″ | rdf:type | schema:Periodical |
174 | sg:person.01004271214.05 | schema:affiliation | grid-institutes:None |
175 | ″ | schema:familyName | Kleinschnitz |
176 | ″ | schema:givenName | C. |
177 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004271214.05 |
178 | ″ | rdf:type | schema:Person |
179 | sg:person.01133657416.38 | schema:affiliation | grid-institutes:None |
180 | ″ | schema:familyName | Schara-Schmidt |
181 | ″ | schema:givenName | U. |
182 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133657416.38 |
183 | ″ | rdf:type | schema:Person |
184 | sg:person.01320640500.40 | schema:affiliation | grid-institutes:None |
185 | ″ | schema:familyName | Hagenacker |
186 | ″ | schema:givenName | T. |
187 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320640500.40 |
188 | ″ | rdf:type | schema:Person |
189 | sg:pub.10.1007/s00115-020-00919-8 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1127514887 |
190 | ″ | ″ | https://doi.org/10.1007/s00115-020-00919-8 |
191 | ″ | rdf:type | schema:CreativeWork |
192 | sg:pub.10.1007/s00234-019-02189-x | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1112731519 |
193 | ″ | ″ | https://doi.org/10.1007/s00234-019-02189-x |
194 | ″ | rdf:type | schema:CreativeWork |
195 | sg:pub.10.1038/ng0797-265 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1051068967 |
196 | ″ | ″ | https://doi.org/10.1038/ng0797-265 |
197 | ″ | rdf:type | schema:CreativeWork |
198 | sg:pub.10.1186/s13023-021-01903-4 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1138847071 |
199 | ″ | ″ | https://doi.org/10.1186/s13023-021-01903-4 |
200 | ″ | rdf:type | schema:CreativeWork |
201 | grid-institutes:None | schema:alternateName | Universitätsmedizin Essen, Klinik für Kinderheilkunde 1, Abteilung für Neuropädiatrie, Essen, Deutschland |
202 | ″ | ″ | Universitätsmedizin Essen, Klinik für Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr. 55, 45147, Essen, Deutschland |
203 | ″ | schema:name | Universitätsmedizin Essen, Klinik für Kinderheilkunde 1, Abteilung für Neuropädiatrie, Essen, Deutschland |
204 | ″ | ″ | Universitätsmedizin Essen, Klinik für Neurologie und Center for Translational Neuro- and Behavioral Science, Hufelandstr. 55, 45147, Essen, Deutschland |
205 | ″ | rdf:type | schema:Organization |